EE04057B1 - 8-asabitsüklo[3,2,1]okt-2-eeni ja -oktaani derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon - Google Patents

8-asabitsüklo[3,2,1]okt-2-eeni ja -oktaani derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon

Info

Publication number: EE04057B1
Authority: EE; Estonia
Prior art keywords: thienyl; azabicyclo; oct; benzofuryl; benzothienyl
Prior art date: 1997-05-30

Application number

EEP199900529A

Other languages

English (en)

Estonian (et)

Inventor

Feldb�k Nielsen Simon

�stergaard Nielsen Elsebet

Peters Dan

M. Olsen Gunnar

Original Assignee

Neurosearch A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-30

Filing date

1998-05-29

Publication date

2003-06-16

1998-05-29 Application filed by Neurosearch A/S filed Critical Neurosearch A/S

2000-06-15 Publication of EE9900529A publication Critical patent/EE9900529A/xx

2003-06-16 Publication of EE04057B1 publication Critical patent/EE04057B1/xx

Links

SURHOQQBDZIWSO-UHFFFAOYSA-N 8-azabicyclo[3.2.1]oct-3-ene Chemical compound N1C2CCC1C=CC2 SURHOQQBDZIWSO-UHFFFAOYSA-N 0.000 title abstract 2
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical class CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
-1 2-(3-methoxymethyl) Chemical group 0.000 abstract 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
230000001713 cholinergic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
230000016160 smooth muscle contraction Effects 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
201000009032 substance abuse Diseases 0.000 abstract 1
231100000736 substance abuse Toxicity 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Psychology (AREA)
Gynecology & Obstetrics (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Hematology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)

EEP199900529A 1997-05-30 1998-05-29 8-asabitsüklo[3,2,1]okt-2-eeni ja -oktaani derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon EE04057B1 (et)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DK62797		1997-05-30
DK150297		1997-12-19
DK40898		1998-03-24
DK53498		1998-04-16
PCT/DK1998/000225 WO1998054181A1 (en)	1997-05-30	1998-05-29	8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors

Publications (2)

Publication Number	Publication Date
EE9900529A EE9900529A (et)	2000-06-15
EE04057B1 true EE04057B1 (et)	2003-06-16

Family

ID=27439314

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP199900529A EE04057B1 (et)	1997-05-30	1998-05-29	8-asabitsüklo[3,2,1]okt-2-eeni ja -oktaani derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon

Country Status (23)

Country	Link
US (2)	US6645977B1 (zh)
EP (1)	EP0984965B1 (zh)
JP (1)	JP4447663B2 (zh)
KR (1)	KR100589872B1 (zh)
CN (1)	CN1157392C (zh)
AT (1)	ATE267199T1 (zh)
AU (1)	AU745964B2 (zh)
BR (1)	BR9809697A (zh)
CA (1)	CA2289574C (zh)
CZ (1)	CZ298824B6 (zh)
DE (1)	DE69823994T2 (zh)
DK (1)	DK0984965T3 (zh)
EE (1)	EE04057B1 (zh)
HK (1)	HK1027353A1 (zh)
HU (1)	HUP0002713A3 (zh)
IL (2)	IL132437A0 (zh)
IS (1)	IS2092B (zh)
NO (1)	NO325513B1 (zh)
NZ (1)	NZ500642A (zh)
RU (1)	RU2186780C2 (zh)
SK (1)	SK284994B6 (zh)
TR (1)	TR199902942T2 (zh)
WO (1)	WO1998054181A1 (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU5790598A (en) *	1996-12-02	1998-06-29	Georgetown University	Tropane derivatives and method for their synthesis
CA2335336A1 (en)	1998-06-19	1999-12-23	James Edmund Audia	Inhibition of serotonin reuptake
US6218383B1 (en) *	1998-08-07	2001-04-17	Targacept, Inc.	Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
DE69914935T2 (de)	1998-11-27	2009-10-01	Neurosearch A/S	8-azabicyclo[3.2.1]okt-2-en- und -oktanderivate
US6953855B2 (en)	1998-12-11	2005-10-11	Targacept, Inc.	3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) *	1998-12-11	2002-08-13	Targacept, Inc.	Pharmaceutical compositions and methods for use
AU2278700A (en) *	1999-01-28	2000-08-18	Neurosearch A/S	Novel azabicyclo derivatives and their use
CZ20012716A3 (cs) *	1999-01-29	2001-11-14	Abbott Laboratories	Diazabicyklické deriváty jako ligandy nikotinového receptoru acetylcholinu
US7265115B2 (en)	1999-01-29	2007-09-04	Abbott Laboratories	Diazabicyclic CNS active agents
ATE261448T1 (de)	1999-05-04	2004-03-15	Neurosearch As	Heteroaryl diazabicycloalkene, deren herstellung und verwendung
US6890935B2 (en)	1999-11-01	2005-05-10	Targacept, Inc.	Pharmaceutical compositions and methods for use
MY137020A (en) *	2000-04-27	2008-12-31	Abbott Lab	Diazabicyclic central nervous system active agents
US7060699B2 (en)	2000-07-04	2006-06-13	Neurosearch A/S	Aryl and heteroaryl diazabicycloalkanes, their preparation and use
NZ524202A (en) *	2000-10-13	2004-08-27	Neurosearch As	Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
WO2003029252A1 (en)	2001-10-02	2003-04-10	Pharmacia & Upjohn Company	Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
WO2003070732A1 (en)	2002-02-19	2003-08-28	Pharmacia & Upjohn Company	Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
WO2003094830A2 (en) *	2002-05-07	2003-11-20	Neurosearch A/S	Novel azacyclic ethynyl derivatives
CN1777596A (zh) *	2003-02-28	2006-05-24	先灵公司	作为选择性mch受体拮抗剂用于治疗肥胖及相关病症的联芳基四氢异喹啉哌啶
WO2004081007A1 (en)	2003-03-12	2004-09-23	Pfizer Products Inc.	Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
EP1802258A4 (en)	2004-09-13	2015-09-23	Chrono Therapeutics Inc	BIOSYNCHRONE TRANSDERMAL MEDICINES
US20060173037A1 (en) *	2005-01-10	2006-08-03	Nathalie Schlienger	Aminophenyl derivatives as selective androgen receptor modulators
ATE495178T1 (de)	2005-02-16	2011-01-15	Neurosearch As	Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin- acetylcholin-rezeptoren
AU2006233884A1 (en) *	2005-04-08	2006-10-19	Neurosearch A/S	(+) - and (-) -8-alkyl-3-(trifluoralkylsulfonyloxy)-8-azabicycl (3.2.1.)oct-2-ene
FR2889701B1 (fr) *	2005-08-12	2007-10-05	Sanofi Aventis Sa	Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique.
KR20080079250A (ko)	2005-12-06	2008-08-29	뉴로서치 에이/에스	신규한 디아자바이사이클릭 아릴 유도체 및 이의 의학적용도
US20070134169A1 (en) *	2005-12-11	2007-06-14	Rabinoff Michael D	Methods for smoking cessation or alcohol cessation or other addiction cessation
AU2007213671A1 (en)	2006-02-10	2007-08-16	Neurosearch A/S	3-heteroaryl- 3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
AU2007213670A1 (en)	2006-02-10	2007-08-16	Neurosearch A/S	3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2641678A1 (en)	2006-02-10	2007-08-16	Neurosearch A/S	3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1977746B8 (en)	2007-04-02	2014-09-24	Parkinson's Institute	Methods and compositions for reduction of side effects of therapeutic treatments
TWI415850B (zh) *	2007-07-20	2013-11-21	Theravance Inc	製備ｍｕ類鴉片受體拮抗劑之中間物的方法
SA08290475B1 (ar)	2007-08-02	2013-06-22	Targacept Inc	(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8697722B2 (en) *	2007-11-02	2014-04-15	Sri International	Nicotinic acetylcholine receptor modulators
WO2010014257A2 (en) *	2008-08-01	2010-02-04	Purdue Pharma L.P.	Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
EP2367818B1 (en) *	2008-11-18	2018-07-25	Initiator Pharma A/S	8-azabicyclo[3.2.1]oct-2-ene derivatives and their use as mono-amine neurotransmitter re-uptake inhibitors
NZ613291A (en)	2008-11-19	2014-11-28	Forum Pharmaceuticals Inc	Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en)	2009-01-26	2010-09-01	Targacept Inc	Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
RU2011150248A (ru) *	2009-05-11	2013-06-20	Энвиво Фармасьютикалз, Инк.	Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
JP5840143B2 (ja)	2010-01-11	2016-01-06	アストライアセラピューティクス，エルエルシーＡｓｔｒａｅａＴｈｅｒａｐｅｕｔｉｃｓ，Ｌｌｃ	ニコチン性アセチルコリン受容体モジュレーター
SG185594A1 (en)	2010-05-17	2012-12-28	Envivo Pharmaceuticals Inc	A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
RU2017136693A (ru)	2012-05-08	2019-02-08	Форум Фармасьютикалз, Инк.	Способы поддержания, лечения или улучшения когнитивной функции
WO2014011768A1 (en) *	2012-07-10	2014-01-16	Adispell, Inc.	Anti-anxiety treatment
WO2016123406A1 (en)	2015-01-28	2016-08-04	Chrono Therapeutics Inc.	Drug delivery methods and systems
US9724340B2 (en)	2015-07-31	2017-08-08	Attenua, Inc.	Antitussive compositions and methods
CA3049529A1 (en)	2017-01-06	2018-07-12	Chrono Therapeutics Inc.	Transdermal drug delivery devices and methods
US11596779B2 (en)	2018-05-29	2023-03-07	Morningside Venture Investments Limited	Drug delivery methods and systems
KR102272452B1 (ko)	2020-12-11	2021-07-05	(주)예광솔라	스파이럴 파일 공법 및 이에 적용되는 스파이럴 파일
KR200497569Y1 (ko)	2021-02-18	2023-12-21	주식회사 알파인랩	지주 기초용 스크루 파일

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3133073A (en) *	1959-12-10	1964-05-12	Sterling Drug Inc	3-aryl-1, 5-iminocycloalkanes and preparation thereof
US3657257A (en) *	1970-08-31	1972-04-18	Robins Co Inc A H	3-aryl-8-carbamoyl nortropanes
CA1244028A (en) *	1983-04-14	1988-11-01	Hans Maag	Pyrimidine derivatives
GB9019973D0 (en)	1990-09-12	1990-10-24	Wyeth John & Brother Ltd	Azabicyclic derivatives
US5045546A (en)	1990-10-26	1991-09-03	Hoechst-Roussel Pharmaceuticals Inc.	8-azabicyclo[3.2.1]octylalkylthiazolidines
FI111367B (fi)	1991-02-04	2003-07-15	Aventis Pharma Inc	Menetelmä terapeuttisesti käyttökelpoisten N-(aryylioksialkyyli)heteroaryyli-8-atsabisyklo[3.2.1]oktaanijohdannaisten valmistamiseksi ja menetelmässä käytetyt välituotteet
EP0588917B1 (en) *	1991-05-29	2000-11-08	Abbott Laboratories	Isoxazole and isothiazole compounds that enhance cognitive function
US5731317A (en) *	1995-03-10	1998-03-24	Merck & Co., Inc.	Bridged piperidines promote release of growth hormone
GB9507203D0 (en) *	1995-04-07	1995-05-31	Smithkline Beecham Plc	Novel compounds
AU7083596A (en) *	1995-09-22	1997-04-09	Novo Nordisk A/S	Novel substituted azacyclic or azabicyclic compounds
TR199800628T2 (xx) *	1995-10-13	1998-07-21	Neurosearch A/S	8-Azabisiklo$3.2.1]okt-2-en t�revleri, bunlar�n haz�rlanmas� ve kullan�m�.
GB9706222D0 (en) *	1997-03-26	1997-05-14	Zeneca Ltd	Bicyclic amine derivatives
EP0955301A3 (en)	1998-04-27	2001-04-18	Pfizer Products Inc.	7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
CA2335336A1 (en) *	1998-06-19	1999-12-23	James Edmund Audia	Inhibition of serotonin reuptake

1998
- 1998-05-29 JP JP50013099A patent/JP4447663B2/ja not_active Expired - Fee Related
- 1998-05-29 DK DK98921378T patent/DK0984965T3/da active
- 1998-05-29 EP EP98921378A patent/EP0984965B1/en not_active Expired - Lifetime
- 1998-05-29 WO PCT/DK1998/000225 patent/WO1998054181A1/en active IP Right Grant
- 1998-05-29 DE DE69823994T patent/DE69823994T2/de not_active Expired - Lifetime
- 1998-05-29 SK SK1626-99A patent/SK284994B6/sk not_active IP Right Cessation
- 1998-05-29 BR BR9809697-4A patent/BR9809697A/pt not_active Application Discontinuation
- 1998-05-29 HU HU0002713A patent/HUP0002713A3/hu unknown
- 1998-05-29 RU RU99128075/04A patent/RU2186780C2/ru not_active IP Right Cessation
- 1998-05-29 IL IL13243798A patent/IL132437A0/xx active IP Right Grant
- 1998-05-29 EE EEP199900529A patent/EE04057B1/xx not_active IP Right Cessation
- 1998-05-29 AT AT98921378T patent/ATE267199T1/de not_active IP Right Cessation
- 1998-05-29 NZ NZ500642A patent/NZ500642A/en unknown
- 1998-05-29 TR TR1999/02942T patent/TR199902942T2/xx unknown
- 1998-05-29 CZ CZ0414799A patent/CZ298824B6/cs not_active IP Right Cessation
- 1998-05-29 CN CNB988054132A patent/CN1157392C/zh not_active Expired - Fee Related
- 1998-05-29 KR KR1019997011137A patent/KR100589872B1/ko not_active IP Right Cessation
- 1998-05-29 AU AU74261/98A patent/AU745964B2/en not_active Ceased
- 1998-05-29 CA CA002289574A patent/CA2289574C/en not_active Expired - Fee Related
1999
- 1999-10-17 IL IL132437A patent/IL132437A/en not_active IP Right Cessation
- 1999-11-10 IS IS5243A patent/IS2092B/is unknown
- 1999-11-29 NO NO19995850A patent/NO325513B1/no not_active IP Right Cessation
- 1999-11-29 US US09/450,637 patent/US6645977B1/en not_active Expired - Fee Related
2000
- 2000-10-10 HK HK00106419A patent/HK1027353A1/xx not_active IP Right Cessation
2003
- 2003-07-17 US US10/620,559 patent/US6964972B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HUP0002713A3 (en)	2001-02-28
IS2092B (is)	2006-04-12
IS5243A (is)	1999-11-10
CN1257499A (zh)	2000-06-21
SK162699A3 (en)	2000-07-11
CA2289574A1 (en)	1998-12-03
IL132437A (en)	2006-12-10
JP2002501514A (ja)	2002-01-15
DE69823994T2 (de)	2009-09-24
EP0984965B1 (en)	2004-05-19
NO995850D0 (no)	1999-11-29
WO1998054181A1 (en)	1998-12-03
EP0984965A1 (en)	2000-03-15
CZ414799A3 (cs)	2000-02-16
CN1157392C (zh)	2004-07-14
US20040019207A1 (en)	2004-01-29
TR199902942T2 (xx)	2000-04-21
AU7426198A (en)	1998-12-30
NZ500642A (en)	2001-11-30
JP4447663B2 (ja)	2010-04-07
NO995850L (no)	1999-11-29
BR9809697A (pt)	2000-07-11
RU2186780C2 (ru)	2002-08-10
US6964972B2 (en)	2005-11-15
ATE267199T1 (de)	2004-06-15
DE69823994D1 (de)	2004-06-24
EE9900529A (et)	2000-06-15
KR20010013154A (ko)	2001-02-26
SK284994B6 (sk)	2006-04-06
HUP0002713A2 (hu)	2001-01-29
KR100589872B1 (ko)	2006-06-15
NO325513B1 (no)	2008-05-26
HK1027353A1 (en)	2001-01-12
IL132437A0 (en)	2001-03-19
US6645977B1 (en)	2003-11-11
DK0984965T3 (da)	2004-09-27
CA2289574C (en)	2007-04-24
AU745964B2 (en)	2002-04-11
CZ298824B6 (cs)	2008-02-20

Publication	Publication Date	Title
EE04057B1 (et)	2003-06-16	8-asabitsüklo[3,2,1]okt-2-eeni ja -oktaani derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
RU99128075A (ru)	2001-09-10	Производные 8-азабицикло(3,2,1)окт-2-ена и-октана в качестве холинергических лигандов на ацх-рецепторах
US8624040B2 (en)	2014-01-07	Substituted hydroxamic acids and uses thereof
CA2041113C (en)	1998-07-14	Thienobenzodiazepine derivatives and their use as pharmaceuticals
US7119205B2 (en)	2006-10-10	Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US7220756B2 (en)	2007-05-22	N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands
AU2003248592A1 (en)	2004-03-03	Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
EP1020445A4 (en)	2001-06-20	CONDENSED PYRIDE DERIVATIVES
CA2521732A1 (en)	2004-10-28	Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
ES2309398T3 (es)	2008-12-16	Derivados 3,4-dihidro-tieno (2,3-d)pirimidin-4-ona-3-sustituidos, produccion y sus usos.
US4735940A (en)	1988-04-05	Tricyclic pyridine derivatives and pharmaceutical compositions
CA2443868A1 (en)	2002-10-24	1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
KR970003440A (ko)	1997-01-28	삼환 5,6-디하이드로-9H-피라졸로[3,4-c]-1,2,4-트리아졸로[4,3-α]피리딘
AU1468901A (en)	2001-05-14	Quinoline and naphthyridine carboxylic acid antibacterials
N. Sangshetti et al.	2014	Synthesis and biological activity of substituted-4, 5, 6, 7-tetrahydrothieno pyridines: a review
MX9205374A (es)	1993-03-01	Piridinil-amino-1h-indoles, 1h-indazoles, 2h-indazoles, benzo(b)tiofenos y 1,2-benzo-isotiazoles sustituidos, un procedimiento para su preparacion y su utilizacion como medicamentos.
CA2501979A1 (en)	2004-04-29	Large conductance calcium-activated k channel opener
US5321021A (en)	1994-06-14	Tricyclic pyridine derivatives
KR880009648A (ko)	1988-10-04	관상질환 또는 유기 뇌 증후군 치료제
ATE15801T1 (de)	1985-10-15	Verfahren zur herstellung von (thienyl-2)-und (thienyl-3)-2 aethylamin-derivaten und so erhaltene verbindungen.
RU2000125685A (ru)	2002-08-27	Модуляторы протеиновых тирозинфосфатаз (птф-аз)

Legal Events

Date	Code	Title	Description
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2010-02-15	KB4A	Valid patent at the end of a year	Effective date: 20091231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2012-02-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20110529